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Objective: Prospective observational study of mycophenolate mofetil (MMF) treatment in
patients with diffuse progressive cutaneous Systemic Sclerosis (SSc) of recent onset.

Methods: Twenty five previously untreated consecutive patients with recent onset (<24 months)
diffuse progressive cutaneous SSc received MMF as the only disease-modifying therapy.
Modified Rodnan skin score (mRSS) and affected body surface area (BSA) were compared from
initiation of MMF to study end. Pulmonary function tests performed at the same institution
before therapy and at study end were available in 15 patients. Histopathology and real time PCR
assessment of fibrosis-related gene expression were performed before and after treatment in skin
biopsies from 3 patients.

Results: At 18.2±8.73 months of MMF therapy (median 2000 mg/day) the mRSS decreased
from 24.56±8.62 to 14.52±10.9 (p=0.0004) and the affected BSA from 36±16% to 14±13.3%
(p=0.00001). Pulmonary function tests remained stable from initiation of MMF to the end of the
study. Skin histopathology showed a remarkable reduction in fibrotic tissue accumulation. Real
time PCR of skin biopsies demonstrated a marked decrease in expression of fibrosis-related
genes.

Conclusion: Patients with diffuse progressive cutaneous SSc of recent onset treated with MMF
experienced marked improvement in skin involvement and stabilization of pulmonary function.
Skin biopsies from 3 patients demonstrated histopathological improvement and decreased
expression of fibrosis-related genes.
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Introduction
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterized by increased
collagen deposition in skin and multiple internal organs, prominent vascular and endothelial
abnormalities and humoral and cellular immune dysregulation (1-3). The introduction of target
organ specific therapies has substantially decreased Systemic Sclerosis (SSc) morbidity and
mortality. In contrast, most studies of potential disease-modifying agents have shown negative
results and currently there is no generally accepted SSc disease modifying therapy.

A major challenge for the evaluation of effectiveness of therapeutic interventions in SSc are the
heterogeneity and variable course of the disease. To mitigate the effects of SSc course variability
and following the paradigm that early intervention is crucial for halting fibrosis most recent
studies selected patients with recent onset of disease (5-9). Disease of recent onset has been
defined in different ways in various studies although a cut-off point of 18-24 months from the
appearance of clinically detectable skin induration is generally accepted. Furthermore, patients
should have substantial skin involvement at treatment initiation to allow detection of
improvement employing the outcome measure tools currently available.

Mycophenolate mofetil (MMF) is an immunosuppressant agent that inhibits proliferative
responses of T and B lymphocytes as well as antibody production by B lymphocytes. It is
indicated for prevention of organ rejection following allogeneic cardiac, hepatic and renal
transplants (10). It is also used for induction and maintenance therapy of lupus nephritis (11,12).
Furthermore, there is evidence that MMF can inhibit fibrosis by acting either directly on
fibroblasts (13) or by inhibiting fibroblast proliferation (14), and by reducing tissue accumulation
of activated myofibroblasts (15).
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Several studies including a recent assessment of 98 patients have described encouraging results
of MMF treatment for SSc (16-20). In contrast, a recent observational trial failed to show
significant differences between four different therapeutic approaches, three of which included
MMF (21). Here, we describe a prospective observational study of MMF for the treatment of
SSc in patients with recent onset of progressive diffuse cutaneous involvement. In contrast with
other published studies (16-20) the patients included in our study had not received any previous
immunosuppresive, immunomodulating, or antifibrotic therapy, and none of the patients received
any other disease modifying therapy during the study.

Patients and Methods
Patient cohort. From December 2006 to December 2009, every new patient with diffuse and
rapidly progressive SSc of recent onset evaluated at our institution was offered treatment with
MMF as disease modifying monotherapy. Only patients with less than 2 years of disease and
mRSS of greater than 12 points who had not received any previous immunosuppressive,
immunomodulatory, or anti-fibrotic therapy were included. Despite the consecutive enrollment
design not all qualifying patients received MMF owing to diverse reasons including most
commonly the denial of insurance reimbursement.

All patients received 500mg twice a day MMF for 3 to 4 weeks and then the dose was escalated
to 1-1.5 g twice a day. Other concomitant medications included calcium channel blockers,
angiotensin converting enzyme inhibitors, proton pump inhibitors, statins and low dose aspirin.
The effects of MMF on the extent and severity of skin involvement employing the modified
Rodnan Skin Score (mRSS) and an estimate of extent of affected body surface area (BSA) were
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assessed as described previously (22). The effects of MMF on SSc severity employing some of
the categories of Medsger’s severity scale (23) were also examined.

The inclusion criteria were: (i) time from onset of clinically detectable skin induration to
initiation of MMF less than 24 months; (ii) diffuse skin involvement at initiation of MMF
affecting the trunk and ⁄or arms and legs proximally to the elbows and ⁄or knees with a mRSS
greater than 12; (iii) no previous treatment with MMF, D-penicillamine, bovine collagen,
cyclophosphamide or any other putative SSc disease modifying drug or intervention; and (iv) the
presence of progressive skin involvement based on information provided by the referring
rheumatologist or by sequential examination at our center.

The exclusion criteria were: (i) skin involvement confined to face or acral regions of the body
(limited cutaneous SSc); (ii) Eosinophillic fasciitis, Nephrogenic Systemic Fibrosis, or other
scleroderma –like diseases; (iii) Mixed connective tissue disease and overlap syndromes; (iv)
prior or current therapy with any other immunosupressant or antifibrotic agent and (v) poor
compliance to medications or follow up.

Study entry was the initiation of MMF treatment and end of study was the last recorded visit. For
data analysis only patients who were followed up for at least 6 months were included.

Assessment of MMF effects on cutaneous and visceral involvement. The extent and severity of
skin involvement was assessed by the mRSS, and the extent of affected BSA was assessed by the
rule of nines employing a burns victim diagram as described previously (22). These parameters
were recorded every 3-6 months during the treatment follow up. Pulmonary function tests,
including total lung capacity (TLC) and diffusion capacity for carbon monoxide (DLCO) were
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monitored every 6 to 12 months during the study. Although chest computerized tomography
(CT) is part of the evaluation and management for all SSc patients at our center CT findings
were not systematically followed up. Percentages and means ± SD were used to describe the
cohort’s demographics. A paired two-tail Student’s t test was used to compare data during the
study period. Because skin involvement continues to increase in extent and severity for a
variable length of time following initiation of therapy in patients with diffuse SSc of recent onset
comparisons of skin involvement were performed between the initial vs final scores and between
the maximal (peak) vs final scores.

Effects of MMF on skin histopathology and fibrosis-related gene expression. Pre- and posttreatment skin biopsies were performed in three patients with their informed consent. Punch
biopsy samples were obtained from affected skin in the dorsum of the forearm. The posttreatment samples were from an area removed approximately 5mm from the initial skin biopsy.
Histopathology assessment was performed in hematoxillin eosin stained skin biopsy samples.
Total RNA was extracted from all the biopsies using RNeasy Fibrous Tissue Kit (Qiagen,
Valencia, CA). Each sample was retro-transcribed using SuperScript II reverse transcriptase
(Invitrogen) and real-time quantitative PCR (rt-PCR) was performed for the expression of
COL1A1, COL1A2, COL4A1, COL14A1, CTGF, FN1, αSMA and TGF- β1. Sequence specific
primers (Table 1) were designed using PrimerQuest (Integrated DNA Technologies, Coralville,
IA). Rt-PCR was performed using SYBR green with an ABI Prism 7900 system (Applied
Biosystems, Carlsbad, CA). The mRNA expression level was normalized by 18s ribosomal
RNA.
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Statistical Analysis. Statistical analysis was performed using a paired Student’s t test. A p value
of < 0.05 was considered statistically significant. Statistical analyses were performed using Excel
and GraphPad Prism programs.
Results
Demographics. There were 35 patients with progressive SSc who fulfilled the classification
criteria for SSc of the American College of Rheumatology (24) and the criteria of LeRoy et al.
(25) for the clinical subset of diffuse cutaneous SSc. All patients had disease of recent onset and
had not received any prior immunomodulatory or immunosuppressive therapy nor any putative
anti-fibrotic agent or intervention. Twenty five patients met the inclusion and exclusion criteria
and were followed at our institution for at least 6 months. The mean ±SD age at initiation of
treatment was 48.6±14.5 years. The majority of the patients were caucasians (76%) with a
smaller proportion of African Americans (12%). The autoantibody profile indicated that 100%
had a positive antinuclear antibody (ANA), by immunofluorescence and 36% (9 patients)
harbored anti-Scl-70 antibodies. The remaining patients were ANA positive but Scl-70 and
anticentromere antibody negative. Analysis for RNA polymerase I/III or other SSc specific
antibodies were not performed in all patients studied. The average duration of therapy was 18.2 ±
8.73 months, and 18 out of 25 (72%) were treated for longer than 1 year. The average dose of
MMF was 2.02 g/day. Only 3 patients had received less than 2 g/d owing to gastrointestinal side
effects.

Clinical assessment of skin involvement and pulmonary function. Clinically detectable skin
induration was first noted at a mean ± SD of 14.1 ± 7.3 months prior to study entry. At the
initiation of therapy the mRSS was 24.56 ± 8.62 units and the affected BSA was 36 ±16%. In
the vast majority of patients a worsening of mRSS and extent of affected BSA was noted
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following entry into the study reaching a peak from 3-6 months after initiation of MMF therapy.
The average time from the first detectable skin involvement to the maximal involvement
(considered as the maximal mRSS) was 20.1 months and the interval between initiation of
treatment to peak mRSS was 6.4 months. Maximal mean ± SD mRSS and BSA were 27.36 ±
9.71 points and 38 ± 15.4%, respectively. The increase in mRSS from the initiation of therapy to
maximal involvement was statistically significant (p=0.0065). Although the increase in BSA
value displayed a similar trend it did not reach statistical significance. (p= 0.069). A significant
reduction of the mRSS and affected BSA was noted from the beginning of therapy to the end of
the study. The mRSS decreased from 24.56 ± 8.62 at entry to 14.52 ± 10.9 (p=0.004) and the
BSA decreased from 36 ± 16% at entry to 14 ± 13.3% (p=0.00001). A more dramatic change
was observed when the peak involvement was compared with the involvement at the end of the
study. The values observed were 27.36 ± 9.7 vs 14.52 ± 10.9 (p= 2.5x10-6) for the mRSS and 38
± 15.4% vs 14 ± 13.3% (p= 9.2x10-7).
Figure 1 shows the mRSS values and extent of BSA treatment initiation (point 1), at peak
involvement (point 2), and at last follow up (point 3). The changes in affected BSA in three
patients in whom skin biopsies were obtained before initiation of MMF therapy and at the end of
the study are pictured in Figure 2. The modified Medsger Severity Score was assessed in all
patients in the study, however, the values represent an underestimate of the severity of the
disease since not all patients with gastrointestinal symptoms were examined by endoscopy or
barium swallow and muscle involvement was not routinely evaluated. Scores for organ
involvement measured by the Medsger Severity Score at initiation of treatment compared with
the scores at study end did not reach statistical significance with the exception of the skin index
that demonstrated a significant reduction (2.2 ± 0.71 versus 1.52± 0.77, p=0.0003).
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The results of pulmonary function tests were analyzed in 15/25 patients who had pre- and posttreatment pulmonary function tests performed at the same institution and were, therefore,
consistent in methodology and equipment utilized. The results in these patients showed that TLC
was 89.47 ± 16.61 % of predicted at study entry compared with 85.33 ± 17.34% at study end
(p=0.13). In this subgroup of 15/25 patients only 3 patients showed a decrease in their TLC
values greater than 10%. The results for DLCO were 69.0% ± 17.51% of predicted at study entry
compared to 70.47% ± 18.84% of predicted at study end (p=0.45).

Tolerability and Adverse Events. All patients tolerated MMF treatment well and in no case was
MMF discontinued owing to intolerance or side effects although in 3 of the 25 patients studied
the dose was reduced to 1-1.5g/day because of gastrointestinal side effects. Ten patients
developed at least one adverse event during MMF treatment. A total of 13 events were recorded.
The most common events were diarrhea (3) and upper respiratory infections (3), followed by
lymphopenia (2), and urinary tract infection (2). One of these 10 patients required a dose
adjustment because of leukopenia. One of the patients in the study died at 18 months of entry.
The cause of dead was a severe and rapidly progressive dilated cardiomyopathy of unkown
etiology. Although it is very unlikely that this event was related to MMF treatment the possibility
that it represented an abrupt deterioration of SSc cardiac involvement or a viral infection
possibly related to immunosupression can not be conclusively established. However, at her last
evaluation following 9 months of MMF therapy and approximately 10 months before her demise
there was a clear reduction in both mRSS and total BSA thus, rendering the possibility that her
demise was SSc related less likely.
Skin histopathological analysis and assessment of fibrosis-related gene expression.
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Histopathological examination and analysis of fibrosis-related gene expression were performed
in pre- and post-treatment skin biopsies obtained from 3 patients. As illustrated in Figure 3,
hematoxyllin-eosin staining showed a remarkable decrease in the abundance and thickness of
collagen bundles and in their compact appearance in the dermis. Similar findings were observed
in skin biopsies stained with Masson’s Trichrome (not shown). There was also very noticeable
re-appearance of hair follicles and sweat and sebaceous glands in the post-treatment biopsies.
Analysis of relative gene expression by real time quantitative PCR, demonstrated a marked
decrease in the relative expression of numerous fibrosis-related genes including COL1A1,
COL1A2, COL 4A1, COL 14A1, CTGF, FN1, αSMA and TGF- β1. (Figure 4).

Discussion
Mycophenolate mofetil, through its biologically active molecule, mycophenolic acid exerts
potent antiproliferative properties resulting from the reversible inhibition of inosine
monophosphate dehydrogenase (IMPDH).

Given the higher sensitivity of the lymphocyte

IMPDH isoform, MMF exerts its effects by causing preferential lymphocyte suppression. On the
other hand, recent studies have shown that MMF is also able to decrease fibroblast proliferation,
an effect which appears to be mediated mainly by IMPDH dependent pathways although IMPDH
independent pathways can also play a role (14,15). It also has been shown that MMF is capable
of direct inhibition of collagen production (13).
The observed degree of improvement of mRSS in the study described here correlates well with
prior studies by Derk et al. (19) and Le et al. (20) who found a reduction of 14.1 and 7.6 points in
the mRSS of patients treated with MMF, respectively. Given the heterogeneous SSc course, the
greater than 10 point mRSS improvement and the 23% reduction in affected BSA observed here
are likely clinically significant for this population of previously untreated patients with SSc of
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recent onset with diffuse cutaneous involvement and usually progressive clinical course.
Furthermore, these results are also superior to our previously published data on D-penicillamine
in a similar population (22). These results are also superior to the spontaneous reduction in
mRSS observed in the placebo control group (-4.6) and in the relaxin-treated group (-4.4) in a
recently published study describing the results of a 24 week randomized control trial of human
recombinant relaxin in a population of SSc patients similar to the one we studied here (26) and to
the -3 point reduction at 15 months in either placebo or treated group in patients with early phase
SSc entering the bovine type I collagen randomized control trial (27).
The clinical improvement we observed correlated well with a remarkable decrease in
histopathological fibrosis, re-appearance of dermal hair follicles and sebaceous and sweat glands,
as well as, with a marked reduction in the expression of numerous fibrosis-related genes in
samples from three patients in whom skin biopsies were obtained before and after therapy. Of
importance was the observation that MMF treatment prevented pulmonary function deterioration
in this population with diffuse SSc of recent onset in whom substantial and significant
deterioration of lung function is highly likely. However, it should be emphasized that the cohort
studied here had only a mild baseline decrease in TLC at study entry, a variable which may have
contributed to slow progression of pulmonary function deterioration as described by Plastiras et
al. (28). The stabilization of lung involvement as assessed by comparison of pulmonary function
tests from initiation of MMF treatment to the end of the study is similar to the results recently
describe by Simeon-Aznar et al in 14 consecutive SSc patients who were treated with 1.5g of
MMF for 12 months (29).
Although the number of patients described here is not large, there are several strengths to our
study including the prospective observational design of our study, and the very strict criteria used
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for defining the study population requiring that only patients with very early (less than 2 years)
and progressive skin disease be included. This is in contrast with populations with much longer
duration of skin disease described in the majority of other studies of SSc disease modifying
interventions. Another strength of our study is that all patients included were naïve to any
immunosupressants or anti-fibrotic treatment and received MMF as the only disease modifying
therapy for the duration of the study.
The selection of patients with early disease was required in order to mitigate the effects of the
variable course of SSc and to address the paradigm that early intervention is crucial for effective
treatment in SSc and other fibrotic diseases. On the other hand, given the relatively low
sensitivity of the current tools for disease assessment the inclusion of patients with moderate to
severe disease was important for demonstrating differences induced by the therapeutic
intervention.
From the safety perspective MMF related adverse events were mild and well tolerated and only
three patients required a dose adjustment. Discontinuation of MMF was not necessary in any
patient. In contrast to the benign pattern of MMF side effects other options for SSc disease
modification, including cyclophosphamide and bone marrow transplant carry substantial and
even fatal potential side effects (30,31). Furthermore, the frequency and severity of adverse
events we observed in this study are not greater than those found in patients with other
autoimmune diseases or in renal transplant patients treated with MMF.
We are aware that owing to the non-placebo controlled design of our study it is not possible to
draw definitive conclusions regarding the efficacy of MMF in modifying SSc disease course.
However, the remarkable degree of clinical improvement observed in this cohort of progressive
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SSc of recent onset which was strongly corroborated by histopathological and gene expression
studies is unlikely to be explained only by the natural evolution of the disease, particularly, in
this group of patients with very early and progressive disease. Furthermore, given the benign
safety profile of MMF our findings suggest that therapy with MMF is safe and effective for SSc
patients with progressive diffuse cutaneous disease of recent onset.
Given the major limitations and substantial challenges in the study of potential SSc disease
modifying treatment prospectively designed double-blind studies will be needed to identify
effective therapeutic interventions for this often devastating disease.
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Table 1: Sequence of primers utilized for real-time PCR

COL 1A1

Forward: CCTCAAGGGCTCCAACGAG

COL1A1

Reverse: TCAATCACTGTCTTGCCCCA

COL1A2

Forward: GGCAAACATGGAAACCGTGGTGAA

COL1A2

Reverse: GGCAGACCTTGCAATCCATTGTGT

COL4A1

Forward: TCCTCATTCTGCATCCTGGCTTGA

COL4A1

Reverse: AAATGGCCCGAATGTGCTTACGTG

COL11A1

Forward: TTGGTCTGCAGTCGCAATTTCGTG

COL11A1

Reverse: TGTTACGGTGAAATCCCAGAGCCA

COL14A1

Forward: AGTCTGGATGGCCACCTACAACAA

COL14A1

Reverse: TTGGTGACCACCGCATGAAGTTTG

CTGF

Forward: CTGCAGGCTAGAGAAGCAGAG

CTGF

Reverse: TTGCCCTTCTTAATGTTCTCTTCC

FN-1

Forward: TTGATGCCGTTTCCAGCCAAT

FN-1

Reverse: AAACGCAGGTTGGATGGTGCAT

αSMA

Forward: TGTATGTGGCTATCCAGGCG

αSMA

Reverse: AGAGTCCAGCACGATGCCAG

TGF-β1

Forward: CGAGCCTGAGGCCGACTA

TGF-β1

Reverse: AGATTTCGTTGTGGGTTTCCA
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Figure 1
Assessment of mRSS. Assessment was performed, at initiation of treatment (point 1), at peak of
skin involvement (point 2), and at last follow up (point 3).

Figure 2
Assessment of total body surface involvement (BSA) in three patients who had skin biopsies
before and after MMF treatment. (A) BSA at the initiation of MMF therapy. (B-D) BSA at serial
follow up evaluations (approximately every three months).

Figure 3
Histopathology of pre treatment (A and C) and post treatment (B and D) hematoxylin-eosin
stained skin biopsies. Images are at 100x magnification. A and B show epidermis and upper
dermis and C and D show lower dermis. Note the remarkable decrease in the thickness and
compact appearance of the collagen bundles, as well the re-population of dermal structures
following MMF treatment.

Figure 4
Relative change in Real Time PCR fibrosis-related gene expression from beginning to end of
treatment in skin biopsy samples from 3 patients. Measurement of various collagen genes
(COL1A1, COL1A2, COL4A1, COL11A1, COL14A1), connective tissue growth factor (CTGF),
fibronectin 1 (FN-1), alpha smooth muscle actin (αSMA) and transforming growth factor beta
(TGF-β) are shown. The horizontal scale shows expression levels (%). Pre-treatment levels were
normalized to 100%.
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